Stroke Risk Assessment and Hormone Therapy Guidance for Postmenopausal Women with Migraine with Aura

Baseline Stroke and Hemorrhage Risk Attributable to Migraine with Aura

• Migraine with aura alone raises the risk of ischemic stroke about 2.5‑fold (relative risk 2.51; 95 % CI 1.52‑4.14) compared with women without migraine【1】.
• Women who experience aura > weekly have an even higher stroke risk (hazard ratio 4.25; 95 % CI 1.36‑13.29)【1】.
• The stroke risk associated with aura is greatest in women younger than 45 years (relative risk 3.65; 95 % CI 2.21‑6.04)【1】.
• Migraine with aura also doubles the risk of intracranial hemorrhage (hazard ratio 2.25; 95 % CI 1.11‑4.54), corresponding to roughly 4 extra events per 10 000 women per year【1】.

Contraindication of Combined Oral Contraceptives (COCs) in Aura Migraine

• Combined oral contraceptives are absolutely contraindicated for women with migraine with aura because they increase ischemic stroke risk about seven‑fold (relative risk 7.02; 95 % CI 1.51‑32.68)【1】.

Absolute Contraindications to Postmenopausal Hormone Therapy (HRT) (Irrespective of Migraine Status)

• History of breast cancer【2】.
• Established coronary heart disease【2】.
• Prior venous thromboembolism or stroke【2】.
• Active liver disease【2】.
• Antiphospholipid syndrome or positive antiphospholipid antibodies【2】.

Compounding Stroke Risk Factors in Women with Aura Migraine

• Active smoking combined with migraine and estrogen produces a catastrophic increase in stroke risk (relative risk 9.03; 95 % CI 4.22‑19.34)【1】.
• Hypertension markedly raises stroke risk and should be aggressively controlled (target < 140/90 mmHg)【3】.
• Thrombophilia (e.g., Factor V Leiden, prothrombin G20210A) amplifies venous thromboembolism risk about 25‑fold when oral estrogen is used【2】.
• Typical migraine phenotype (absence of nausea/vomiting) is associated with higher stroke risk【1】.

Decision Framework for Initiating HRT in Aura Migraine

• If two or more of the above compounding risk factors are present, estrogen therapy is strongly discouraged.
• When zero or one additional risk factor is identified, HRT may be considered for severe vasomotor symptoms provided no absolute contraindications exist【2】.

Preferred HRT Formulation and Route

• Transdermal estrogen is strongly preferred over oral formulations because it avoids first‑pass hepatic metabolism and does not increase VTE risk, even in women with pro‑thrombotic mutations【2】.
• Oral estrogen doubles the risk of venous thromboembolism compared with placebo【2】.

Mandatory Concurrent Interventions When HRT Is Prescribed

• Complete tobacco abstinence is mandatory given the catastrophic stroke risk associated with smoking【1】.
• Aggressive blood‑pressure control to a target < 140/90 mmHg is required【3】.
• Screening for thrombophilia should be performed before initiating oral estrogen in at‑risk women.

Non‑Hormonal Alternatives for Severe Vasomotor Symptoms (When HRT Is Contraindicated or Declined)

• Venlafaxine or escitalopram provide dual benefit for hot flashes and migraine prophylaxis【4】.
• Gabapentin is effective for both hot‑flash reduction and decreasing migraine frequency【4】.
• Cognitive‑behavioral therapy, yoga, and acupuncture are supported non‑pharmacologic options for symptom relief【4】.

Management of Worsening Migraines During Hormone Replacement Therapy (HRT)

Hormone Regimen Adjustments

• When migraine frequency or severity increases during HRT, clinicians should modify the hormone regimen—adjusting dose, changing the route of administration, or altering the dosing schedule—rather than discontinuing therapy altogether. 5
• For migraine‑friendly HRT, 17‑beta estradiol is preferred over ethinylestradiol or conjugated equine estrogens because it provides more stable estrogen levels and is less likely to trigger migraine attacks. 5, 6

Contraindications to HRT

• Absolute contraindications to HRT include a prior history of breast cancer, coronary heart disease, venous thromboembolism, stroke, or active liver disease; women with any of these conditions should not receive HRT. 7
• Women diagnosed with antiphospholipid syndrome should avoid HRT entirely due to heightened thrombotic risk. 7

Acute Migraine Management During HRT

• First‑line acute treatment of migraine episodes in women on HRT should be non‑steroidal anti‑inflammatory drugs (NSAIDs) such as ibuprofen, diclofenac potassium, or acetyl‑salicylic acid. 8
• If NSAIDs are insufficient, second‑line therapy consists of triptans administered early in the headache course while pain is still mild. 8

Non‑Hormonal Dual‑Benefit Therapies

• Venlafaxine or escitalopram can be used to simultaneously alleviate vasomotor (hot‑flash) symptoms and provide migraine prophylaxis. 6
• Gabapentin has demonstrated efficacy for both hot‑flash reduction and decreasing migraine frequency or severity, offering an alternative when hormonal adjustments are not feasible. 6

Migraine Management in Perimenopause

Hormone Replacement Therapy

• The American College of Obstetricians and Gynecologists recommends that migraine should not be considered a contraindication to HRT use in perimenopausal women, unlike the absolute contraindication for combined hormonal contraceptives in women with migraine with aura, according to the Human Reproduction Update 9
• If migraine worsens during HRT, consider changing the dose, route of administration, or regimen, as suggested by the Human Reproduction Update 10, 9